Kristen Galfetti

VP, IR & Corporate Communications , Titan Medical Inc.

Ms. Galfetti is Vice President, Investor Relations & Corporate Communications at Titan Medical Inc, a surgical robotics company. She has over 20 years of experience leading investor relations and corporate communications programs. Prior to joining Titan, Ms. Galfetti provided consulting services to small and medium companies in the life science industries.

Her previous corporate experience includes serving as Vice President, Investor Relations & Corporate Communications at Cynapsus Therapeutics until Cynapsus was acquired in an industry leading all-cash transaction with Sunovion Pharmaceuticals Inc. for CAD $841 million. Prior to Cynapsus, she was Senior Director, Investor Relations at Sanofi, responsible for integrating the Genzyme Corporation investor relations program post-merger. Prior to Sanofi, Ms. Galfetti was Senior Director, Corporate Communications and Investor Relations at AMAG Pharmaceuticals, where she created the communications function. Prior to AMAG, Ms. Galfetti held Investor Relations roles of increasing responsibility at Genzyme Corporation. Ms. Galfetti holds a Bachelor of Arts in Political Science from the University of Vermont and a Master of Business Administration (with distinction) from Bentley University